Study of Temzolomide and Gleevec in Advanced Melanoma

Exclusion Criteria

• •No prior treatment with temozolomide or imatinib mesylate
• •Organ allografts
• •Prior radiotherapy, or prior intratumor injection therapy, to areas of measurable disease that are used as target indicator lesions, unless progression has occurred at that site or measurable disease has developed outside the treatment area
• •Pregnancy or lactation
• •History of second cancer
• •Known hypersensitivity to temozolomide or imatinib
• •Use of any experimental therapy within 3 weeks prior to baseline evaluations done prior to enrollment